Retraction: Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting —Practice and Outcomes

Retraction: Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes Frontiers Editorial Office* A Retraction of the Original Research Article Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes by Abdo, J., Bertellotti, C. A., Cornell, D. L., Agrawal, D. K., and Mittal, S. K. (2017). Front. Oncol. 7:151. doi: 10.3389/fonc.2017.00151 The journal retracts the 18 July 2017 article cited above. During a recent review by the Creighton University Institutional Review Board that approved this study, it was found that the authors utilized and included some datasets that were not IRB-approved. Therefore, the study did not receive full ethics committee approval and is being withdrawn. The authors concur with the retraction and sincerely regret any inconvenience this may have caused to the reviewers, editors, and readers of Frontiers in Oncology. Citation: Frontiers Editorial Office (2019) Retraction: Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes. Front. Oncol. 9:324. doi: 10.3389/fonc.2019.00324 Received: 10 April 2019; Accepted: 10 April 2019; Published: 24 April 2019. Approved by: Giuseppe Giaccone, Georgetown University, United States Copyright © 2019 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research